Skip to content Skip to footer

Tag: REGN

HomeAll PostsTag: REGN
Parabilis Medicines, Inc. (NASDAQ: PBLS) entered public markets with the kind of financial runway, strategic endorsement and clinical ambition that tends to make biotech investors sit up straighter in their Aeron chairs. The Cambridge-based clinical-stage company is pursuing a deceptively simple proposition: use…
For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…